Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: A California Cancer Consortium Trial

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 373-378

  Morgan Jr , R J ^a   Synold, T W ^a   Gandara, D ^b   Muggia, F ^c   Scudder, S ^b   Reed, E ^d   Margolin, K ^a   Raschko, J ^a   Leong, L ^a   Shibata, S ^a   Tetef, M ^a   Vasilev, S ^a   McGonigle, K ^a   Longmate, J ^a   Yen, Y ^a   Chow, W ^a   Somlo, G ^a   Carroll, M ^a   Doroshow, J H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemomodulation; Chemotherapy; Phase II

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CYCLOSPORIN A;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG EFFECT; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FLUID RETENTION; GRANULOCYTOPENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; LOADING DRUG DOSE; NAUSEA AND VOMITING; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALIFORNIA; CARBOPLATIN; CARCINOMA; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 33947226126     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00787.x     Document Type: Article

References (25)

1. Atkinson K. Cyclosporin in bone marrow transplantation. Bone Marrow Transplant 1987;1:265-70.
2. Twentyman PR. Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporines. Br J Cancer 1988;57:254-58.
3. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992;43:109-17.
4. Kashani-Sabet M, Wang W, Scanlon KJ. Cyclosporine A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 1990;265:11285-88.
5. Scanlon KJ, Wang W, Han H. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat Rev 1990;17(Suppl. A):27-35.
6. Charak B, Sadowski R, Mazumder A. Antitumor effect of interferon plus cyclosporine A following chemotherapy for disseminated melanoma. Cancer Res 1992;52:6482-86.
7. Jozan S, Courtade M, Mathieu-Boue A et al. Cytotoxic effect of interferon-α2a in combination with all-trans retinoic acid or cisplatin in human ovarian carcinoma cell lines. Anticancer Drugs 1998;9:229-38.
8. Berek J, Markman M, Stonebraker B et al. Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol 1999;75:10-4.
9. Morgan RJ Jr, Margolin K, Raschko J et al. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. J Clin Oncol 1995;13:2238-46.
10. Green S, Weiss G. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
11. D'Argenio D, Shumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115-34.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Paietta E, Andersen J, Racevskis J et al. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group. Blood Rev 1995;9:47-52.
15. Manetta A, Boyle J, Berman ML et al. Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer 1994;73:196-99.
16. Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990;36:1969-73.
17. Vogt W, Welsch I. Modified TDx assay for cyclosporine and metabolites, for use with whole-blood samples. Clin Chem 1988;34:1459-61.
18. Lensmeyer GL, Wiebe DA, Carlson IH. Identification and analysis of nine metabolites of cyclosporine in whole blood by liquid chromatography. 1: Purification of analytical standards and optimization of the assay. Clin Chem 1987;33:1841-50.
19. Yahanda AM, Adler KM, Fisher GA et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992;10:1624-34.
20. Sonneveld P, Durie BGM, Lokhorst HM et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-59.
21. Chambers SK, Chambers JT, Davis CA et al. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol 1997;15:1945-52.
22. Chambers SK, Davis CA, Chambers JT et al. Phase I trial of intravenous carboplatin and cyclosporine A in refractory gynecologic cancer patients. Clin Cancer Res 1996;2:1699-04.
23. Chambers SK, Davis CA, Schwartz PE et al. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. Clin Cancer Res 1996;2:1693-97.
24. Li Q, Tsang B, Bostick-Bruton F et al. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 1999;57:347-53.
25. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a Phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42.